Volume | 768,906 |
|
|||||
News | - | ||||||
Day High | 4.90 | Low High |
|||||
Day Low | 3.93 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Syros Pharmaceuticals Inc | SYRS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.00 | 3.93 | 4.90 | 4.02 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,266 | 768,906 | $ 4.35 | $ 3,347,219 | - | 2.0902 - 5.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:12:04 | 60 | $ 4.7272 | USD |
Syros Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
99.86M | 21.07M | - | 14.88M | -94.65M | -4.49 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Syros Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SYRS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.74 | 4.90 | 2.47 | 3.90 | 976,841 | 1.98 | 72.37% |
1 Month | 2.95 | 4.90 | 2.47 | 3.73 | 305,275 | 1.77 | 60.1% |
3 Months | 3.94 | 4.90 | 2.0902 | 3.52 | 141,011 | 0.7829 | 19.87% |
6 Months | 3.78 | 4.90 | 2.0902 | 3.53 | 98,578 | 0.9429 | 24.94% |
1 Year | 3.38 | 5.67 | 2.0902 | 3.62 | 105,502 | 1.34 | 39.73% |
3 Years | 8.69 | 15.6499 | 0.65 | 4.28 | 558,174 | -3.97 | -45.65% |
5 Years | 7.45 | 15.6499 | 0.65 | 5.31 | 451,193 | -2.73 | -36.61% |
Syros Pharmaceuticals Description
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States. |